Latest News

  • 07.18.17 - Looking for a comprehensive resource on cervical cancer? CDC’s fact ... read more »
  • 07.08.17 - The Harvard T.H. Chan School of Public Health published new ... read more »
  • 06.30.17 - Researchers from Yale University have developed a new model to ... read more »

Read more news stories »

New ASCO Guidelines

The American Society of Clinical Oncology (ASCO) has published its first resource-stratified guidelines on the clinical practice of invasive cervical cancer. The report, published in the Journal of Global Oncology (May, 2016), classifies the new recommendations into four tiers: basic, limited, enhanced, and maximal.  

Some of the key recommendations are:

  • In basic settings where patients cannot be treated with radiation therapy, extrafascial hysterectomy either alone or after chemotherapy may be an option for women with stage IA1 to IVA cervical cancer.
  • Concurrent radiotherapy and chemotherapy is standard in enhanced and maximal settings for women with stage IB to IVA disease.The panel stresses the addition of low-dose chemotherapy during radiotherapy, but not at the cost of delaying radiation therapy if chemotherapy is not available in limited settings.
  • For patients with stage IV or recurrent cervical cancer, single-agent chemotherapy (carboplatin or cisplatin) is recommended in basic settings.
  • Where resources are constrained, single- or short-course radiotherapy schemes can be used with retreatments if feasible for persistent or recurrent symptoms.

You can see the full guidelines here:

http://jgo.ascopubs.org/content/early/2016/05/21/JGO.2016.003954.full

preloaded image 0 preloaded image 1 preloaded image 2 preloaded image 3 preloaded image 4 preloaded image 5 preloaded image 6 preloaded image 7